Ask the Experts: Practical Guidance for Designing Successful Targeted Protein Degradation Assays

In this webinar, we will:

  • Share tips we have learned in developing target degradation assays for numerous proteins
  • Provide suggestions for assays to understand target binding, ubiquitination and compound permeability
  • Answer your questions on degrader assay design and interpretation


The field of targeted protein degradation (TPD) continues to expand. New opportunities are emerging for targeting disease-causing proteins that were previously viewed as undruggable. As the field has matured, the community has learned more about how the available tools can be used to identify and validate new degrader compounds. In this webinar, our TPD experts will address commonly asked questions and share best practices for developing degrader assays to help you overcome known challenges and advance your degrader research. The webinar also includes a live Q&A session.



Kristin Riching, PhD
Senior Research Scientist

Kristin Riching received her Ph.D. from the University of Wisconsin–Madison, where she studied the structural and mechanical properties of collagen fibers and their effects on breast cancer cell migration in invasive ductal carcinoma. She then worked as a postdoctoral researcher at Promega studying ligand-induced protein interactions within the ErbB signaling network and their roles in cancer progression. She has been at Promega for four years and is currently a Senior Scientist developing approaches to monitor functional mechanisms of proteasome-mediated protein degradation.


James Vasta, PhD
Senior Research Scientist

At Promega, James is focused on the development and application of target engagement technologies to investigate drug-target interactions in live cells using NanoBRET. He is broadly interested in applying this technology to many target families and enabling key applications such as live-cell selectivity profiling and live-cell evaluations of compound permeability and intracellular availability. Prior to joining the team at Promega, James received his Ph.D. in Biochemistry from the University of Wisconsin-Madison, where he focused on developing inhibitors for the collagen prolyl 4-hydroxylases (CP4Hs), a group of enzymes implicated in myriad diseases including fibrosis, scurvy, and cancer. James has contributed to the discovery and patenting of a novel and selective human CP4H inhibitor, which is currently in pre-clinical investigations. Lastly, James received his Bachelor of Science in Biochemistry from Lafayette College in Easton, Pennsylvania, where he focused on using analytical methodologies to discover small-molecule biomarkers of parasitic infections.

We love to talk science.

Sign up to receive monthly invitations to our webinars.

Sign Up